David L Boyle1, Samuel E DePrimo2, Cesar Calderon3, Dion Chen4, Paul J Dunford3, William Barchuk3,5, Gary S Firestein1, Robin L Thurmond6. 1. Division of Rheumatology, Allergy and Immunology, UC San Diego School of Medicine, La Jolla, San Diego, CA, USA. 2. Immunology Biomarkers, Janssen Research & Development LLC, San Diego, CA, USA. 3. Immunology Clinical Development, Janssen Research & Development LLC, Spring House, PA, USA. 4. Biostatistics, Janssen Research & Development LLC, Spring House, PA, USA. 5. Immunology Clinical Development, Eli Lilly and Company, San Diego, CA, USA. 6. Immunology Clinical Development, Janssen Research & Development LLC, Spring House, PA, USA. RThurmon@its.jnj.com.
Abstract
OBJECTIVE/ DESIGN: In a double-blind, placebo-controlled, multiple-dose study, we assessed the molecular mechanism of action of the selective histamine-4-receptor antagonist toreforant. PATIENTS/TREATMENT: Patients with active rheumatoid arthritis (RA) despitemethotrexate were randomized (3:1) to toreforant 30 mg/day (weeks 0-52) or placebo (weeks 0-12) followed by toreforant 30 mg/day (weeks 12-52). METHODS: Primary biomarker analyses comprised 39 different proteins/mRNA transcripts measured in synovial biopsy (n = 39) and/or time-matched serum (n = 15) samples collected at baseline and week 6. Clinical response was assessed using C-reactive protein-based 28-joint disease activity scores. Data were summarized using descriptive statistics. RESULTS: Among 21 randomized, treated patients (toreforant-16, placebo-5), 18 (toreforant-13, placebo-5) completed the 12-week double-blind period (none completed open-label treatment) prior to the early study termination. Biomarker profiling indicated potential modest effects of toreforant on gene expression of histamine-1-receptor, tumor necrosis factor-alpha, and interleukin-8 in synovium. Potential trends between biomarkers and clinical response were observed with synovial monocyte chemoattractant protein-4 and phosphorylated extracellular-signal-regulated kinases and serum matrix metalloproteinase-3. Minimal synovial gene expression of interleukins-17A and 17F was detected. CONCLUSIONS: While clear biomarker signals associated with toreforant pharmacology in RA patients were not identified, modest associations between biomarkers and clinical response were noted. Synovial expression of interleukins-17A/17F was minimal. Limited sample size warrants cautious interpretation.
RCT Entities:
OBJECTIVE/ DESIGN: In a double-blind, placebo-controlled, multiple-dose study, we assessed the molecular mechanism of action of the selective histamine-4-receptor antagonist toreforant. PATIENTS/TREATMENT: Patients with active rheumatoid arthritis (RA) despite methotrexate were randomized (3:1) to toreforant 30 mg/day (weeks 0-52) or placebo (weeks 0-12) followed by toreforant 30 mg/day (weeks 12-52). METHODS: Primary biomarker analyses comprised 39 different proteins/mRNA transcripts measured in synovial biopsy (n = 39) and/or time-matched serum (n = 15) samples collected at baseline and week 6. Clinical response was assessed using C-reactive protein-based 28-joint disease activity scores. Data were summarized using descriptive statistics. RESULTS: Among 21 randomized, treated patients (toreforant-16, placebo-5), 18 (toreforant-13, placebo-5) completed the 12-week double-blind period (none completed open-label treatment) prior to the early study termination. Biomarker profiling indicated potential modest effects of toreforant on gene expression of histamine-1-receptor, tumornecrosis factor-alpha, and interleukin-8 in synovium. Potential trends between biomarkers and clinical response were observed with synovial monocyte chemoattractant protein-4 and phosphorylated extracellular-signal-regulated kinases and serum matrix metalloproteinase-3. Minimal synovial gene expression of interleukins-17A and 17F was detected. CONCLUSIONS: While clear biomarker signals associated with toreforant pharmacology in RApatients were not identified, modest associations between biomarkers and clinical response were noted. Synovial expression of interleukins-17A/17F was minimal. Limited sample size warrants cautious interpretation.
Authors: T Iwamoto; H Okamoto; N Iikuni; M Takeuchi; Y Toyama; T Tomatsu; N Kamatani; S Momohara Journal: Rheumatology (Oxford) Date: 2005-11-22 Impact factor: 7.580
Authors: H P Kiener; R Hofbauer; M Tohidast-Akrad; S Walchshofer; K Redlich; P Bitzan; S Kapiotis; G Steiner; J S Smolen; P Valent Journal: Arthritis Rheum Date: 2000-01
Authors: A Kavanaugh; S Rosengren; S J Lee; D Hammaker; G S Firestein; K Kalunian; N Wei; D L Boyle Journal: Ann Rheum Dis Date: 2007-07-20 Impact factor: 19.103
Authors: David L Boyle; Sanna Rosengren; William Bugbee; Arthur Kavanaugh; Gary S Firestein Journal: Arthritis Res Ther Date: 2003-10-08 Impact factor: 5.156